SecBot SecBot

IMTX

Immatics N.V.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. P7· CIK 0001809196 Biotech & Drug Discovery
$6.17 −0.22 (−3.44%)
Nov 16 4:00 PM ET · prev $6.39
Market cap
$975.6M
Small cap
Consensus
Buy
94% Buy or better · 17 analysts
Median target
$15.00
+143% · range $11.80–21.00
1 year
−34.8%
from $9.47 · Nov 17
30 days
−12.5%
from $7.05
52-week range
$6.17–11.87
at the low
Avg volume 20D
1.09M
shares / day
Short interest
3.67M
≈2.5% of shares · −2.1%
Days to cover
3.0
at average volume
Insider net
+$7.5M
1 buyer · 0 sellers · 12 mo
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
16
analyzed by SecBot
SecBot read BULLISH 9 reports · 90 days
Balance 1 bearish · 4 bullish · 4 neutral oldest → newest, height = score
Avg score ·High conf. 6/9

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBULLISH

    1 insider bought $7.5M at an average $8.69. No open-market sales. Price is 29% below their cost.

  • InstitutionsBULLISH

    Q3 2026: 13 added (0 new), 4 trimmed or exited.

  • AnalystsBULLISH

    16 of 17 rate it Buy or better. Every target is above the price.

  • EstimatesFLAT

    Current-quarter EPS estimate −$0.497 → −$0.496 over 90 days. 2 up, 0 down in 30 days.

  • Short sellersSTEADY

    Short interest −2.1% to 3.67M shares. 3.0 days to cover, ≈2.5% of shares.

  • TrendDOWNTREND

    19% below its 50-day average. New closing low $6.17 on Nov 16.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
Aberdeen Group plcADD1,235,460$10.8M
Qube Research & Technologies LtdADD991,278$8.7M
JANE STREET GROUP, LLCDOUBLED399,661$3.5M
HRT FINANCIAL LPDOUBLED265,513$2.3M
ALPS ADVISORS INCADD198,239$1.7M
BlackRock, Inc.DOUBLED115,187$1.0M
Jump Financial, LLCTRIM72,023$632.4K
CITIGROUP INCTRIM46,683$409.9K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

17 analysts
Buy 94% rate it Buy or better
Strong Buy8Buy8Hold1Sell0Strong Sell0
12-month targets · 7 analysts

Price is below the lowest target. Median implies +143%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Oct 14, 2026Stifel
INITIATE
INITIATEBuy

Insider ledger

Form 4
$7.5M
bought · 1 insider
$0
sold · 0 insiders
−29.0%
vs their $8.69 cost
DateInsiderTypeValue
Aug 26, 2026
PERCEPTIVE ADVISORS LLC
Director
Aug 26, 2026
BUY$7.5M
Aug 14, 2026
Pepin James Nelson
Gen Counsel and Corp Secretary
Aug 14, 2026
AWARD181,200 sh
Aug 14, 2026
Pepin James Nelson
Gen Counsel and Corp Secretary
Aug 14, 2026
AWARD43,800 sh
Jun 16, 2026
Chambre Peter Alan
Director
Jun 16, 2026
AWARD48,000 sh
Jun 16, 2026
Forster Eliot
Director
Jun 16, 2026
AWARD48,000 sh
Jun 16, 2026
Carter Paul Rutherford
Director
Jun 16, 2026
AWARD48,000 sh
Jun 16, 2026
ATIEH MICHAEL G
Director
Jun 16, 2026
AWARD48,000 sh
Jun 16, 2026
Hothum Mathias
Director
Jun 16, 2026
AWARD48,000 sh

Earnings setup

Estimates
−$0.50
EPS estimate, this quarter
+0%
estimate change, 90 days
2↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.50-$0.54–-$0.42+1.5%$9.1M
Next Q-$0.59-$0.67–-$0.52-0.3%$5.5M
Current FY🔒 Fresh data, subscribers only
Next FY-$1.98-$2.27–-$1.63+2.2%$31.4M

Short side

FINRA· Oct 30, 2026
3,669,476
shares short
-2.1%
vs prior settlement
3.0
days to cover
≈2.5%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 16, 2026 Earnings calendar
IMTX Q3 2026 Earnings Scheduled · 2026-11-16
Nov 13, 2026 SEC
Montanova Capital, LLC filed Amendment No. 4 to its Schedule 13G, reporting beneficial ownership of 8,750,816 ordinary…
SC 13G/A · Impact 2/10
Nov 10, 2026 SEC
Immatics reported Q3 2026 collaboration revenue of EUR 6.9M (up 33% YoY) and a net loss of EUR 76.0M (up 50% YoY)…
6-K · Impact 5/10
Oct 24, 2026 Press
Immatics presented updated Phase 1b data for IMA402 PRAME bispecific and Phase 1 data for IMA203CD8 PRAME cell therapy…
Impact 6/10
Sep 30, 2026 Inst.
Aberdeen Group plc · ADD
1,235,460 shares ($10.8M)
Sep 30, 2026 Inst.
Qube Research & Technologies · ADD
991,278 shares ($8.7M)
Aug 26, 2026 Insider
PERCEPTIVE ADVISORS LLC bought 863,060 shares
Director @ $8.69 ($7.5M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
3 drugs tracked · Drug pipeline →
Recent

SecBot reports

16 filings · 7 press releases · 6 bullish · 2 bearish · 2 mixed · 6 neutral
All IMTX filing & press-release reports (23)